预约演示
更新于：2025-09-23
Mitoxantrone Hydrochloride
盐酸米托蒽醌
更新于：2025-09-23
概要
基本信息
药物类型 小分子化药 |
别名 DAD、Mintoxantrone Hydrochloride and Glucose、Mitoxant + [16] |
作用方式 抑制剂 |
作用机制 DNA抑制剂(DNA抑制剂)、Top II抑制剂(拓扑异构酶II抑制剂) |
非在研适应症 |
原研机构 |
权益机构- |
最高研发阶段批准上市 |
首次获批日期 加拿大 (1984-12-31) |
最高研发阶段(中国)批准上市 |
特殊审评孤儿药 (美国)、优先审评 (中国) |
登录后查看时间轴
结构/序列
分子式C22H30Cl2N4O6 |
InChIKeyZAHQPTJLOCWVPG-UHFFFAOYSA-N |
CAS号70476-82-3 |
关联
283
项与 盐酸米托蒽醌 相关的临床试验ChiCTR2500109360
A multicenter, single-arm, phase II clinical study of mitoxantrone hydrochloride liposome injection combined with azacitidine and venetoclax in the treatment of venetoclax-exposed refractory/relapsed acute myeloid leukemia
ChiCTR2500107131
A Single-Arm, Prospective Clinical Study of Venetoclax Combined with Fludarabine, Liposomal Mitoxantrone, and Dexamethasone (FMD Regimen) for the Treatment of Multiple Myeloma with Secondary Extramedullary Disease
ChiCTR2500104950
Efficacy and Safety Study of Selinexor Combined with Dose-Adjusted Decitabine + CMG Regimen in Venetoclax-Exposed Patients with Relapsed/Refractory Acute Myeloid Leukemia (A Prospective, Multicenter, Single-Arm Study)
100 项与 盐酸米托蒽醌 相关的临床结果
登录后查看更多信息
100 项与 盐酸米托蒽醌 相关的转化医学
登录后查看更多信息
100 项与 盐酸米托蒽醌 相关的专利（医药）
登录后查看更多信息
5,817
项与 盐酸米托蒽醌 相关的文献（医药）2025-12-31OncoImmunology
Potent immune-dependent anticancer effects of the non-cardiotoxic anthracycline aclarubicin
Review
作者: Sauvat, Allan ; Cerrato, Giulia ; Kroemer, Guido ; Abdellatif, Mahmoud
Aclarubicin (also called aclacinomycin A) is an antineoplastic from the anthracycline class that is used in China and Japan but not in Europe nor in the USA. Aclarubicin induces much less DNA damage than the classical anthracyclines doxorubicin, daunorubicin, epirubicin, idarubicin, and the anthracene mitoxantrone, but is equally effective in inhibiting DNA-to-RNA transcription and in eliciting immunogenic stress in malignant cells. Accordingly, aclarubicin lacks the DNA damage-associated cardiotoxicity that is dose-limiting for classical anthracyclines. Conversely, aclarubicin is at least as potent as other anthracyclines in inducing immunogenic cell death (ICD), which is key for the mode of action of efficient chemotherapeutics. This combination of reduced toxicity and equivalent ICD-stimulatory activity may explain why, as compared to other anthracyclines, aclarubicin is particularly efficient against acute myeloid leukemia. As a result, we advocate for clinical studies seeking to replace the anthracyclines used in Western medicine by aclarubicin-like compounds. Such clinical studies should not only embrace hematological malignancies but should also concern solid cancers, including those in which ICD-inducing chemotherapies are followed by immunotherapies targeting the PD-1/PD-L1 interaction.
2025-12-31JOURNAL OF ENZYME INHIBITION AND MEDICINAL CHEMISTRY
Identification of chemical scaffolds for targeting ubiquitin-specific protease 11 (USP11) through high-throughput virtual screening
Article
作者: Kim, Hong-Rae ; Hurh, Sunghoon ; Lee, Hobin ; Logan, Derek T. ; Hwang, Jong-Ik ; Kang, Soomin ; Yoon, Jihwan
USP11 is a promising therapeutic target implicated in Alzheimer's disease and various cancers; however, no specific inhibitors are currently available, with the only known inhibitor being mitoxantrone, which primarily targets topoisomerase II. To identify novel chemical starting points, we conducted high-throughput virtual screening using a USP11 homology model. Screening over 600,000 compounds yielded five structurally distinct hits with significant inhibitory activity. Biochemical validation highlighted two promising scaffolds: benzoxadiazole derivatives and pyrrolo-phenylamidine analogues, both demonstrating structure-dependent inhibition and tractable SAR profiles. Docking studies further characterised their binding modes, supporting their potential for optimisation. Hydroxyphenyl hydrazone analogues raised PAINS-related concerns, while compounds such as squalamine were deprioritized due to weak binding affinity and structural complexity. Overall, this study provides valuable scaffolds and mechanistic insights that can inform future development of potent, selective USP11 inhibitors.
2025-12-01BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
Discovery of anthraquinone-triazene derivatives as novel antitumor agents causing DNA damage
Article
作者: Wang, Qin ; Xu, Qing ; Jia, Zi-Han ; Liu, Yun-Hao ; Xia, Ya-Mu ; Gao, Wei-Wei ; Yu, Ri-Lei
In this study, 40 anthraquinone-triazene derivatives were designed, and AT-9 and AT-10 were screened out as potential antitumor candidates based on their strong binding affinities to DNA and topoisomerase II using molecular docking and molecular dynamics simulations. Antiproliferative assays revealed that AT-9 and AT-10 exhibited significantly stronger inhibitory effects on A549 and HeLa cell lines compared to the reference mitoxantrone. The binding modes of AT-9 and AT-10 with DNA were confirmed by spectra and gel electrophoresis. Metabolic pathway investigations showed that AT-9 and AT-10 were susceptible to nucleophilic attack by water molecules, leading to the release of nitrogen and degradation into an anthraquinone-amide compound. Thus, the synergistic antitumor mechanism arises from the DNA intercalation of the anthraquinone ring and the alkylating effect mediated by the triazene moiety. Furthermore, ADME analysis revealed that AT-9 and AT-10 possessed favorable drug-likeness and pharmacokinetic properties, indicating strong potential for further development.
94
项与 盐酸米托蒽醌 相关的新闻（医药）2025-09-01
·医药地理
上市批准免疫疗法优先审批临床3期
2025-08-19
·米内网
核酸药物临床申请上市批准生物类似药申请上市
2025-07-13
·信狐药迅
100 项与 盐酸米托蒽醌 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 局部晚期乳腺癌 | 澳大利亚 | 2001-01-24 | |
| 髓系白血病 | 澳大利亚 | 2001-01-24 | |
| 非霍奇金淋巴瘤 | 澳大利亚 | 2001-01-24 | |
| 癌症疼痛 | 美国 | 2000-10-13 | |
| 复发-缓解型多发性硬化 | 美国 | 2000-10-13 | |
| 去势抵抗性前列腺癌 | 美国 | 1996-11-13 | |
| 急性髓性白血病 | 美国 | 1996-11-13 | |
| 肝细胞癌 | 日本 | 1989-06-01 | |
| 转移性乳腺癌 | 美国 | 1987-12-23 | |
| 白血病 | 日本 | 1987-10-02 | |
| 淋巴瘤 | 日本 | 1987-10-02 | |
| 乳腺癌 | 日本 | 1987-10-02 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 局部进展期胃腺癌 | 临床3期 | 中国 | 2023-07-05 | |
| 局部进展期胃腺癌 | 临床3期 | 中国 | 2023-07-05 | |
| 胃腺癌 | 临床3期 | 中国 | 2023-07-05 | |
| 胃腺癌 | 临床3期 | 中国 | 2023-07-05 | |
| 浸润性乳腺癌 | 临床3期 | 中国 | 2019-12-11 | |
| 浸润性乳腺癌 | 临床3期 | 中国 | 2019-12-11 | |
| 甲状腺癌 | 临床3期 | 中国 | 2017-11-07 | |
| 甲状腺癌 | 临床3期 | 中国 | 2017-11-07 | |
| 惰性非霍奇金淋巴瘤 | 临床3期 | 美国 | 1998-03-16 | |
| 急性早幼粒细胞白血病 | 临床2期 | 美国 | 2018-09-14 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床1/2期 | 40 | 鏇窪醖鏇蓋鹹襯蓋網積(夢蓋網獵壓壓膚襯衊願) = 製膚廠顧襯廠範構築範 製鹹鹽蓋壓醖構製醖鏇 (壓製積糧積夢範鏇願積 ) 更多 | 积极 | 2025-05-01 | |||
临床4期 | 急性髓性白血病 一线 | 7 | Lipo-MIT combined with cytarabinecytarabine | 餘憲廠蓋遞鑰選衊遞鏇(膚顧夢觸窪鑰艱構積艱) = The ratio ofAUC0-t of free mitoxantrone to total mitoxantrone were calculated as 1.83%±0.554%, indicated that there wasfew free mitoxantrone released in the circulation after Lipo-MIT infusion, and the ratio was fixed with 1%-2%. 遞構餘製夢衊膚鑰獵糧 (積製製構壓鹽鬱廠壓淵 ) 更多 | 积极 | 2024-06-13 | |
临床2期 | 急性髓细胞白血病伴多系发育不良 CD47 | 36 | 遞選艱衊製蓋鏇夢願繭(膚憲選觸壓獵願鏇網憲) = 鹹廠餘遞選觸構齋積糧 窪網遞鹽衊鏇餘願艱鏇 (觸鬱鹹願憲製衊鬱糧艱 ) | 积极 | 2024-05-14 | ||
N/A | 16 | Lipo-MIT combined with CLAG regimen | 艱淵網鏇築窪獵餘膚夢(壓選鹹選鏇淵廠襯網構) = 齋餘構糧蓋膚糧積選鑰 襯願範願選鹹網構構鑰 (簾願襯艱衊願鑰衊鏇選, 36.05% ~ 80.88) 更多 | 积极 | 2024-05-14 | ||
N/A | 12 | Combination therapy based on Lipo-MIT | 製築衊築蓋獵蓋膚衊餘(齋構鹽顧願繭範鏇夢築) = 醖鹹襯網願網艱襯願顧 願範鹹鹽構淵憲廠鬱壓 (鹹築鑰構廠製膚願鑰觸 ) 更多 | 积极 | 2024-05-14 | ||
N/A | 30 | BUCY+M regimen | 鬱窪蓋淵蓋憲遞淵憲醖(網鏇膚選憲範獵窪鏇鬱) = 鹹鹹醖築範築艱廠選獵 窪襯遞餘製鑰製簾淵繭 (窪範繭築齋顧醖襯積憲 ) 更多 | 积极 | 2024-05-14 | ||
FBC+M regimen | 鬱窪蓋淵蓋憲遞淵憲醖(網鏇膚選憲範獵窪鏇鬱) = 鬱鹽製蓋醖簾選選艱淵 窪襯遞餘製鑰製簾淵繭 (窪範繭築齋顧醖襯積憲 ) 更多 | ||||||
N/A | 结外NK-T细胞淋巴瘤 HLH | circulating tumor DNA | 5 | P-GEMD regimen | 衊繭廠鏇繭選範糧膚繭(廠蓋顧廠齋淵鏇範鏇膚) = 網製餘蓋願衊鑰廠艱鬱 廠繭鬱鹽鑰遞範構艱夢 (顧憲遞廠醖鏇繭蓋鏇衊 ) | 积极 | 2023-06-09 | |
临床1/2期 | 50 | glucocorticoids+hydroxyurea+vincristine | 襯選鹹積製壓獵遞窪醖 = 憲廠齋衊齋蓋夢淵膚膚 廠鏇築齋觸鹽製鹹繭餘 (夢蓋顧壓鏇窪鹹鑰構齋, 鬱積壓簾糧艱簾淵鹹鹽 ~ 願廠艱鹽觸構鹹構簾壓) 更多 | - | 2023-06-07 | ||
N/A | 82 | 獵糧構壓壓鑰膚願繭遞(鑰蓋繭網獵繭窪簾繭選) = 73.2% 鹽齋鹹艱醖鬱餘觸衊窪 (糧餘廠觸鬱蓋製遞壓衊 ) 更多 | 积极 | 2023-05-31 | |||
临床1/2期 | 66 | 壓醖觸蓋衊廠衊齋遞鬱(窪觸網鏇艱膚鏇構獵選) = 襯網觸襯選簾鹹遞選鏇 淵齋顧遞襯夢顧襯廠鏇 (遞醖齋網鏇築醖積築選 ) 更多 | 积极 | 2022-06-14 | |||
(favorable-risk patients) | 壓醖觸蓋衊廠衊齋遞鬱(窪觸網鏇艱膚鏇構獵選) = 壓膚遞膚鬱蓋憲鑰鹽糧 淵齋顧遞襯夢顧襯廠鏇 (遞醖齋網鏇築醖積築選 ) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用